Full-Time
Praktikant:in im Service Außendienst Medizintechnik im Raum Hamburg
Hannover, Bremen, m/w/d
Updated on 7/22/2026
Roche
1-10 employees
Global pharmaceuticals and diagnostics company
Compensation Overview
€2.3k/mo
Lengede, Germany + 3 more
More locations: Bremerhaven, Germany | Walsrode, Germany | Hamburg, Germany
Hybrid
Hybrid work: some tasks may be done remotely; most work on-site with customers.
 Hardware Engineering (1) |
|---|
Get referred to Roche
Find people who can refer or advise you
- You study currently successfully in an engineering science field (e.g. Medical Engineering, Electrical Engineering, Bioengineering, Mechatronics or comparable) or you are in a gap year between Bachelor and Master studies.
- In the areas of electronics, mechanics, hydraulics, IT interfaces or measurement technology you could ideally already have initial theoretical or practical experience.
- You are not only theoretically enthusiastic about complex technologies but also demonstrate practical hands-on skill and a hands-on mentality.
- You have an affinity for modern IT topics (e.g. network technology, cybersecurity and firewalls).
- The service field force (outside sales service) fascinates you and you are eager to dive deeper into the dynamic diagnostic field.
- You have a valid driver's license class B and look forward to varied business travel within your regional service area. You can flexibly choose your place of residence within the area.
- Very good, negotiation-ready German language skills (spoken and written) are a given for professional communication with our customers and partners.
- Accompany our experienced employees in planning, installation, maintenance and modification of our analysis systems cobas pro and cobas pure.
- Delve into the IT networking of our systems during daily field deployments at various hospital and private laboratories.
- Receive comprehensive training at the start of the internship on our immunology cobas systems and be intensively accompanied by a mentor throughout the entire field service deployment.
- Work with customers on site and in the team to solve complex technical and applicative issues and support root-cause analysis.
- Contribute to the areas Clinical Chemistry and Immunology, with the possibility of hospitations to learn about other company areas.
- Learn IT networks and IT security by installing firewalls with our IT specialists.
- Take on defined task packages independently (e.g. professional briefing of customers on the use of our online platform Navify).
- Develop communication skills through direct dialogue with customers and coordination within the team.
- Flexibly handle smaller project tasks on some days in the home office; most time on site with customers.
- We offer an attractive, appreciative internship environment with room for growth and steep learning curves.
- We provide a company car, a smartphone, a laptop and professional tools for your deployments; we cover hotel expenses.
- None
Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.
Company Size
1-10
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1896
Get referred to Roche
Find people who can refer or advise you
Simplify's Take
What believers are saying
- Roche targets top-three obesity status by 2030 via CT-388 and petrelintide assets.
- The $1.5B Poseida acquisition secures off-the-shelf CAR-T therapies for oncology and immunology.
- AI-driven diagnostics gain traction through the $750M PathAI acquisition closing in 2026 H2.
What critics are saying
- Kadcyla and Perjeta biosimilar erosion in 2025–2026 will strip billions from oncology revenue.
- Ocrevus loss of exclusivity in 2029 threatens the entire immunology franchise profitability.
- Eight cancer drugs face biosimilars by 2030, risking CHF 6.7B sales decline easily.
What makes Roche unique
- Roche uniquely integrates Pharmaceuticals and Diagnostics under one roof for personalized healthcare.
- Only Roche combines world-class drug R&D with global diagnostics leadership seamlessly.
- Roche leverages companion diagnostics to pair targeted therapies with precise patient identification.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Company News
SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.
Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.
Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.
Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.
Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.